TheraRadar
← Back
Data updated: Jun 28, 2026

THE J MOLNER

Generics

THE J MOLNER is a generic drug manufacturer focused on Infectious Disease, Dermatology.

2004
Since
5
Drugs
-
Trials
0
New Drugs (2yr)

Upcoming FDA Decisions

Full Calendar →
Jul 11, 2026 — Relacorilant + nab-paclitaxel
0d
Jul 23, 2026 — Rivoceranib + camrelizumab
Jul 23, 2026 — Rivoceranib + camrelizumab

THE J MOLNER's Key Drugs

THE J MOLNER's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

THE J MOLNER's Recent FDA Approvals

New NDA/BLA approvals for THE J MOLNER over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

THE J MOLNER's Therapeutic Areas

THE J MOLNER's approved drugs and pipeline span 2 therapeutic areas, led by Infectious Disease and Dermatology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 50%
1 drugs
Dermatology 50%
1 drugs

THE J MOLNER's Top Competitors

THE J MOLNER's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and B BRAUN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

THE J MOLNER Pipeline Snapshot

Active clinical trials for THE J MOLNER across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Infectious Disease pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling